Cancer Pain - Pipeline Review, H1 2014
Cancer Pain - Pipeline Review, H1 2014
Summary
Global Markets Directs, Cancer Pain ...
r&d Progress 83
tanezumab - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
saracatinib - Dr...
r&d Progress 107
ddrnai Program For Cancer-associated Pain - Drug Profile 108
product Description 108
mechanism Of Action ...
apr 05, 2013: Phosphagenics Receives Approval To Conduct Clinical Study Of Oxycodone Patch At Royal Adelaide Hospital 143
...
Upcoming SlideShare
Loading in …5
×

Cancer Pain - Pipeline Review, H1 2014: Industry Overview

322 views

Published on

Cancer Pain - Pipeline Review, H1 2014 @ http://www.researchmoz.us/cancer-pain-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
322
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Cancer Pain - Pipeline Review, H1 2014: Industry Overview

  1. 1. Cancer Pain - Pipeline Review, H1 2014 Cancer Pain - Pipeline Review, H1 2014 Summary Global Markets Directs, Cancer Pain - Pipeline Review, H1 2014, provides an overview of the Cancer Pains therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cancer Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Rofile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 tk-641 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 tapentadol Hydrochloride Er - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 hydromorphone - Drug Profile 83 product Description 83 mechanism Of Action 83 Cancer Pain - Pipeline Review, H1 2014
  2. 2. r&d Progress 83 tanezumab - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 saracatinib - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 (morphine + Oxycodone) Cr - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 arx-02 - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 morphine Sulfate Er - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 fulranumab - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 sufentanil - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 dexmedetomidine Hydrochloride - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 fentanyl - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 pgn-202 - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 fentanyl Citrate Sr - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 leconotide - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 dronabinol - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 vby-825 - Drug Profile 103 product Description 103 mechanism Of Action 103 r&d Progress 103 zucapsaicin - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 ang-2002 - Drug Profile 106 product Description 106 mechanism Of Action 106 r&d Progress 106 z-360 - Drug Profile 107 product Description 107 mechanism Of Action 107 Cancer Pain - Pipeline Review, H1 2014
  3. 3. r&d Progress 107 ddrnai Program For Cancer-associated Pain - Drug Profile 108 product Description 108 mechanism Of Action 108 r&d Progress 108 nktr-192 - Drug Profile 110 product Description 110 mechanism Of Action 110 r&d Progress 110 buprenorphine Hydrochloride Er - Drug Profile 111 product Description 111 mechanism Of Action 111 r&d Progress 111 af-353 - Drug Profile 112 product Description 112 mechanism Of Action 112 r&d Progress 112 int-0028 - Drug Profile 114 product Description 114 mechanism Of Action 114 r&d Progress 114 dd-04107 - Drug Profile 115 product Description 115 mechanism Of Action 115 r&d Progress 115 qx-314 - Drug Profile 116 product Description 116 mechanism Of Action 116 r&d Progress 116 ifenprodil - Drug Profile 117 product Description 117 mechanism Of Action 117 r&d Progress 117 calpastatin - Drug Profile 118 product Description 118 mechanism Of Action 118 r&d Progress 118 small Molecule To Antagonize Chemokine Receptor For Cancer Pain - Drug Profile 119 product Description 119 mechanism Of Action 119 r&d Progress 119 kls-2010 - Drug Profile 120 product Description 120 mechanism Of Action 120 r&d Progress 120 ph Alpha-1-beta - Drug Profile 121 product Description 121 mechanism Of Action 121 r&d Progress 121 bbi-11008 - Drug Profile 122 product Description 122 mechanism Of Action 122 r&d Progress 122 cpc-703 - Drug Profile 123 product Description 123 mechanism Of Action 123 r&d Progress 123 cancer Pain - Recent Pipeline Updates 124 cancer Pain - Dormant Projects 138 cancer Pain - Discontinued Products 139 cancer Pain - Product Development Milestones 140 featured News & Press Releases 140 feb 18, 2014: Preclinical Data On Angiochem Pain Program Published In Journal Of Clinical Investigation 140 feb 10, 2014: Sorrento Therapeutics Expands Its Exclusive Rights To Cynviloq To Include Australia, Canada And Mexico 140 dec 05, 2013: Orion Settles Patent Dispute Over The Proprietary Drug Precedex 141 jul 29, 2013: Biodelivery Sciences Announces Regulatory Approval Of Onsolis In Taiwan 141 may 10, 2013: Durect Announces Pfizer's Update On Investigational Pain Drug Remoxy 142 may 09, 2013: Purdue Pharma To Present Data Regarding Long-term Opioid Therapy At Aps Annual Meeting 142 Cancer Pain - Pipeline Review, H1 2014
  4. 4. apr 05, 2013: Phosphagenics Receives Approval To Conduct Clinical Study Of Oxycodone Patch At Royal Adelaide Hospital 143 apr 03, 2013: Gw Pharma Receives Us Patent Allowance For Delivery Of Sativex Formulation 143 feb 14, 2013: Us Federal Court Validates Cephalons Fentora Patents 144 oct 15, 2012: Biodelivery Sciences Announces Launch Of Breakyl In Eu 144 appendix 145 methodology 145 coverage 145 secondary Research 145 primary Research 145 expert Panel Validation 145 contact Us 146 disclaimer 146 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Cancer Pain - Pipeline Review, H1 2014

×